Data monitoring committees for clinical trials evaluating treatments of COVID-19

Area of Science:

• Clinical Trial Management
• Epidemiology
• Biostatistics

Background:

• The emergence of coronavirus disease 2019 (COVID-19) and its declaration as a pandemic necessitated urgent research into diagnostics, vaccines, and treatments.
• High mortality rates associated with COVID-19 underscore the critical need for robust safety monitoring in clinical trials.
• Data Monitoring Committees (DMCs), also known as Data Safety Monitoring Boards (DSMBs), are essential for overseeing the safety and integrity of clinical trials.

Purpose of the Study:

• To provide a perspective on the operational and statistical challenges faced by DMCs during COVID-19 clinical trials.
• To discuss organizational aspects of establishing and managing DMCs for COVID-19 treatment trials, including complex designs like platform and adaptive trials.
• To offer recommendations for data presentation, safety monitoring stopping rules, and the utilization of external data in COVID-19 clinical trial monitoring.

Main Methods:

• Review and discussion of organizational and statistical aspects relevant to DMCs in the context of COVID-19 clinical trials.
• Consideration of challenges such as rapid patient recruitment, frequent safety reviews, and the use of complex trial designs.
• A simulation study was conducted to assess proposed stopping boundaries for safety monitoring, motivated by COVID-19 clinical trial scenarios.

Main Results:

• DMCs encountered significant challenges during COVID-19 trials, including accelerated recruitment timelines and the increased use of complex adaptive or platform trial designs.
• The paper outlines specific recommendations for enhancing DMC effectiveness, focusing on data review, stopping criteria, and external data integration.
• Simulation results provided an assessment of the proposed stopping boundaries, offering data-driven insights for safety monitoring in similar future trials.

Conclusions:

• Effective DMC operations are crucial for the successful and ethical conduct of clinical trials during public health emergencies like the COVID-19 pandemic.
• Addressing the unique challenges through tailored organizational strategies and statistical approaches can improve the efficiency and rigor of safety monitoring.
• The recommendations and simulation-based assessments presented aim to guide future DMCs in managing complex trials, particularly in rapidly evolving disease outbreaks.